Clinical Trials Logo

Hemophilia B With Inhibitor clinical trials

View clinical trials related to Hemophilia B With Inhibitor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05651061 Completed - Clinical trials for Hemophilia A With Inhibitor

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Start date: December 14, 2022
Phase: Phase 1
Study type: Interventional

This phase I study aims to evaluate the safety, PK/PD and immunogenicity of SS109 in hemophilia A or and B with inhibitors. Twenty -seven patients are enrolled in study, and divided into five dose cohorts, from 30μg/kg to 360μg/kg. Dose 1 cohort enrolls three patients, each other dose cohorts enroll six patients. All patients included in the study will continue to be followed up until 28 days after SS109 administration.

NCT ID: NCT04789954 Completed - Clinical trials for Hemophilia A With Inhibitor

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Start date: December 29, 2020
Phase: Early Phase 1
Study type: Interventional

Randomized, double-blind, single-dose, 5 ways crossover, exploratory clinical trial evaluating four different doses of AryoSeven (eptacog alfa, activated) and NovoSeven on selected pharmacodynamic parameters in patients with hemophilia with inhibitors.

NCT ID: NCT04072237 Completed - Hemophilia A Clinical Trials

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Start date: September 24, 2019
Phase: Phase 1
Study type: Interventional

This multi-center, open label Phase 1 study will evaluate the pharmacokinetics, pharmacodynamics, and safety of a single IV dose of MarzAA followed by ascending single SC doses of MarzAA in adult subjects with moderate or severe Hemophilia A or B, with or without an inhibitor.

NCT ID: NCT03818529 Completed - Hemophilia A Clinical Trials

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Start date: October 3, 2018
Phase:
Study type: Observational

This is a multi-center cohort study of approximately 250 previously untreated patients (PUPs) with congenital moderate to severe hemophilia A or B in a network of up to 50 US Hemophilia Treatment Centers (HTCs). Participants will be followed as they receive their first 50 exposure days (ED) to clotting factor replacement product, both prospectively and retrospectively. The data collected on evolving treatment practices will define the incidence and risk factors for inhibitor development during the high risk period of first 50 ED and improve the outcomes of this vulnerable population.

NCT ID: NCT03407651 Completed - Clinical trials for Hemophilia A With Inhibitor

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Start date: December 18, 2017
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, open-label study designed to evaluate the PK, bioavailability, PD, efficacy and safety of a daily subcutaneous [SC] treatment regimen with MarzAA for bleeding prophylaxis in 12 adult subjects with hemophilia A or B with an inhibitor and history of frequent spontaneous bleeding episodes.

NCT ID: NCT03372993 Completed - Clinical trials for Hemophilia A With Inhibitor

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Start date: June 13, 2016
Phase:
Study type: Observational

This study evaluates the immunogenicity of the biosimilar rFVIIa (AryoSeven) in subjects receiving AryoSeven in real-life clinical practice.